Endothelial dysfunction: The early predictor of atherosclerosis

Cardiovascular Journal of Africa

Volumn 23, Issue 4, 2012, Pages 222-231

  Mudau, Mashudu ^a   Genis, Amanda ^a   Lochner, Amanda ^a   Strijdom, Hans ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Atherosclerosis; Endothelial dysfunction; Endothelium; eNOS uncoupling; Nitric oxide bioavailability; Oxidative stress

Indexed keywords

3 NITROTYROSINE; ATORVASTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUINDOSTATIN; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PRAVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADD ON THERAPY; AGING; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR RISK; CELL PROLIFERATION; CIRCULATING ENDOTHELIAL CELL; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MICROPARTICLE; ENDOTHELIUM CELL; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PREDICTOR VARIABLE; REVIEW; SHEAR STRESS; SMOKING; SMOOTH MUSCLE FIBER; UPREGULATION;

ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE; OXIDATIVE STRESS; RISK FACTORS;

EID: 84861323605     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: 10.5830/CVJA-2011-068     Document Type: Review

References (93)

1. Steyn K. Heart Disease in South Africa. In: Fourie JM (ed). Chronic diseases of lifestyle unit. Medical Research Council (MRC) media data document. MRC, 2007.
2. World Health Organisation (WHO). Global health risks: Mortality and burden of disease attributable to selected major risks. Geneva: WHO, 2009.
3. Lahoz C, Mostaza JM. Atherosclerosis as a systemic disease. Rev Esp Cardiol 2007; 60(2): 184-195. (Pubitemid 46566972)
4. Choi D, Hwang K-C, Lee K-Y, Kim Y-H. Ischemic heart disease: current treatments and future. J Contr Release 2009; 140: 194-202.
5. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: Testing and clinical relevance. Circulation 2007; 115: 1285-1295. (Pubitemid 46594773)
6. Yang G, Lucas R, Caldwell R, Yao L, Romero MJ, Caldwell RW. Novel mechanisms of endothelial dysfunction in diabetes. J Cardiovasc Dis Res 2010; 1(2): 59-63.
7. Chhabra N. Endothelial dysfunction - A predictor of atherosclerosis. Internet J Med Update 2009; 4(1): 33-41.
8. Bijl M. Endothelial activation, endothelial dysfunction and premature atherosclerosis in systemic autoimmune disease. Neth J Med 2003; 60: 273-277. (Pubitemid 39089423)
9. Rabelink TJ, De Boer CH, van Zonneveld AJ. Endothelial activation and circulating markers of endothelial activation in kidney disease. Nat Rev Nephrol 2010; 6: 404-414.
10. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-175. (Pubitemid 36231924)
11. Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharon JL, Machado RA. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 2006; 5: 4.
12. Strijdom H, Lochner A. Cardiac endothelium: More than just a barrier! SA Heart 2009; 6(3): 174-185.
13. Strijdom H, Chamane N, Lochner A. Nitric oxide in the cardiovascular system: a simple molecule with complex actions. Cardiovasc J Afr 2009; 20: 303-310.
14. Bruckdorfer R. The basics about nitric oxide. Mol Aspect Med 2005; 26: 3-31. (Pubitemid 40250163)
15. Moncada S, Palmer RM, Higgs EA. The discovery of nitric oxide as the endogenous nitrovasodilator. Hypertension 1988; 12: 365-372.
16. Balligand J-L, Cannon PJ. Nitric oxide synthases and cardiac muscle: autocrine and paracrine influences. Arterioscler Thromb Vasc Biol 1997; 17: 1846-1858. (Pubitemid 28057081)
17. Bryan NS, Bian K, Murad F. Discovery of the nitric oxide signaling pathway and targets for drug development. Front Biosci 2009; 14: 1-18.
18. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001; 357: 593-615. (Pubitemid 32735142)
19. Dudzinski D, Michel T. Life history of eNOS: partners and pathways. Cardiovasc Res 2007; 75(2): 247-260. (Pubitemid 46961923)
20. Förstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006; 113: 1708-1714.
21. Potenza MA, Gagliardi S, Nacci C, et al. Endothelial dysfunction in diabetes: From mechanisms to therapeutic targets. Curr Med Chem 2009; 16: 94-112.
22. Hsueh WA, Lyon CJ, Quinones MJ. Insulin resistance and the endothelium. Am J Med 2004; 117: 109-117. (Pubitemid 38953731)
23. Guzik TJ, Mussa S, Gastaldi D, et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus, role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002; 105: 1656-1662. (Pubitemid 34298608)
24. Avogaro A, de Kreutzenberg S, Fadini G. Endothelial dysfunction: causes and consequences in patients with diabetes mellitus. Diabetes Res Clin Pract 2008; 82: S94-S101.
25. Soldatos G, Cooper ME, Jandeleit-Dahm KAM. Advanced-glycation end products in insulin-resistant states. Curr Hypertens Rep 2005; 7: 96-102. (Pubitemid 40796727)
26. Versari D, Daghini E, Virdis A, et al. Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol 2009; 157: 527-536.
27. Sawamura T. LOX-1, a lectin-like oxidized LDL receptor identified form endothelial cells, in endothelial dysfunction. Int Congr 2004; 1262: 531-534.
28. Böger RH, Bode-Böger S, Szuba A, et al. Asymmetric dimethlyarginine (ADMA): a novel risk factor for endothelial dysfunction, its role in hypercholesterolemia. Circulation 1998; 98: 1842-1847. (Pubitemid 28509278)
29. Böger RH, Vallance P, Cooke JP. Asymmetric dimethlyarginine (ADMA): a key regulator of nitric oxide synthase. Atherosclerosis Suppl 2003; 4: 1-3. (Pubitemid 38234488)
30. Zeibig S, Li Z, Wagner S, et al. Effect of the ox-LDL binding protein Fc-CD68 on plaque extension and vulnerability in atherosclerosis. Circ Res 2011; 108(6): 695-703.
31. Boulanger CM, Tanner FC, Bea ML, et al. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium Circ Res 1992; 70: 1191-1197.
32. Warnholtz A, Mollnau H, Oelze M, et al. Antioxidants and endothelial dysfunction in hyperlipidemia. Curr Hypertens Rep 2001; 3: 53-60.
33. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109: 27-32.
34. Hamburg NM, Vita JA. Endothelial dysfunction in atherosclerosis: mechanisms of impaired nitric oxide bioactivity. In: Loscalzo J (ed). Molecular Mechanisms of Atherosclerosis. London: Taylor and Francis 2005: 95-110.
35. Bhatt SR, Lokhandwala MF, Banday AA. Resveratrol prevents endothelial nitric oxide synthase uncoupling and attenuates development of hypertension in spontaneously hypertensive rats. Eur J Pharmacol 2011; 667(1-3): 258-264.
36. Tang EH, Vanhoutte PM. Endothelial dysfunction: a strategic target in the treatment of hypertension? Pflugers Arch 2010; 459(6): 995-1004.
37. Paniagua OA, Bryant MB, Panza JA. Role of endothelial nitric oxide in shear stress-induced vasodilation of human microvasculature: diminished activity in hypertensive and hypercholesterolemic patients. Circulation 2001; 103: 1752-1758. (Pubitemid 32291412)
38. Iaccarino G, Ciccarelli M, Sorriento D, et al. AKT participates in endothelial dysfunction in hypertension. Circulation 2004; 109: 2587-2593. (Pubitemid 38720561)
39. Puranik R, Celermajer DS. Smoking and endothelial function. Progr Cardiovasc Dis 2003; 45: 443-458. (Pubitemid 36666452)
40. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation 2005; 111: 2684-2698. (Pubitemid 40740869)
41. Burke A, FitzGerald GA. Oxidative stress and smoking-induced vascular injury. Progr Cardiovasc Dis 2003; 46: 79-90. (Pubitemid 37013220)
42. Antoniades C, Tousoulis D, Stefanadis C. Smoking in Asians: it doesn't stop at vascular endothelium. Int J Cardiol 2008; 128: 151-153.
43. Katusic ZS. Mechanisms of endothelial dysfunction induced by aging, role of arginase I. Circ Res 2007; 101: 640-641. (Pubitemid 47494091)
44. Herrera MD, Mingorance C, Rodríguez- Rodríguez R, et al. Endothelial dysfunction and aging: an update. Ageing Res Rev 2010; 9: 142-152.
45. Vanhoutte PM. Ageing and endothelial dysfunction. Eur Heart J Suppl 2002; 4: A8-A17.
46. Pennathur S, Heinecke JW. Oxidative stress and endothelial dysfunction in vascular disease. Curr Diabetes Rep 2007; 7: 257-264. (Pubitemid 47249084)
47. Landmesser U, Harrison DG, Drexler H. Oxidant stress - a major cause of reduced endothelial nitric oxide availability in cardiovascular disease. Eur J Clin Pharmacol 2006; 63: 13-19.
48. Yokoyama M. Oxidant stress and atherosclerosis. Curr Opin Pharmacol 2004; 4: 110-115. (Pubitemid 38444044)
49. Huang PL. Endothelial nitric oxide synthase and endothelial dysfunction. Curr Hypertens Rep 2003; 5: 473-480. (Pubitemid 38898972)
50. Kuzkaya N, Weissmann N, Harrison DG, et al. Interaction of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols. J Biol Chem 2003; 278: 22546-22554.
51. Katusic ZS. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? Am J Physiol Heart Circ Physiol 2001; 281: 981-986.
52. Zou M-H, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 2002; 109: 817-826. (Pubitemid 34263158)
53. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 150: 1135-1143. (Pubitemid 34212626)
54. Osto E, Cosentino F. The role of oxidative stress in endothelial dysfunction and vascular inflammation. In: Ignarro LJ (ed). Nitric Oxide: Biology and Pathobiology. 2nd edn. London: Academic Press 2010: 705-754.
55. Szmitko PE, Wang C-H, Weisel RD, et al. New markers of inflammation and endothelial cell activation, part 1. Circulation 2003; 108: 1917-1923. (Pubitemid 37296533)
56. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 29-38. (Pubitemid 40054251)
57. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001; 89: 763-771. (Pubitemid 34633846)
58. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol Regulatory Intergrative Comp Physiol 1998; 274: 577-595.
59. Fain JN, Bahouth SW, Madan AK. TNF-α release by the nonfat cells of human adipose tissue. Int J Obes 2004; 28: 616-622. (Pubitemid 38491155)
60. Zhang H, Park Y, Wu J, et al. Role of TNF-α in vascular dysfunction. Clin Sci 2009; 116: 219-230.
61. Gao X, Belmadani S, Picchi A, et al. Tumor necrosis factor-α induces endothelial dysfunction in Leprdb mice. Circulation 2007; 115: 245-254. (Pubitemid 46105724)
62. Stenvinkel P. Endothelial dysfunction and inflammation - is there a link? Nephrol Dial Transplant 2001; 16: 1968-1971. (Pubitemid 32970552)
63. Zhang C, Xu X, Potter BJ, Wang W, et al. TNF-α contributes to endothelial dysfunction in ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol 2006; 26: 475-480.
64. Balakumar P, Kaur T, Singh M. Potential target sites to modulate vascular endothelial dysfunction: current perspectives and future directions. Toxicology 2008; 245(1-2): 49-64.
65. Münzel T, Sinning C, Post F, et al. Pathophysiology, diagnosis and prognostic implication of endothelial dysfunction. Ann Med 2008; 40: 180-196. (Pubitemid 351482543)
66. Green DJ, Jones H, Thijssen D, Cable NT, Atkinson G. Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter? Hypertension 2011; 57(3): 363-369.
67. Kim F, Gallis B, Corson MA. TNF-alpha inhibits flow and insulin signaling leading to NO production in aortic endothelial cells. Am J Physiol Cell Physiol 2001; 280(5): C1057-1065.
68. Bove K, Neumann P, Gertzberg N, Johnson A. Role of ecNOS-derived NO in mediating TNF-induced endothelial barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 2001; 280(5): L914-922
69. Xia Z, Luo T, Liu HM, Wang F, Xia ZY, Irwin MG, Vanhoutte PM. L-arginine enhances nitrative stress and exacerbates tumor necrosis factor-alpha toxicity to human endothelial cells in culture: prevention by propofol. J Cardiovasc Pharmacol 2010; 55(4): 358-367.
70. Goodwin BL, Pendleton LC, Levy MM, Solomonson LP, Eichler DC. Tumor necrosis factor-alpha reduces argininosuccinate synthase expression and nitric oxide production in aortic endothelial cells. Am J Physiol Heart Circ Physiol 2007; 293(2): H1115-1121. (Pubitemid 47254212)
71. Kiettisanpipop P, Lertsapcharom P, Chotivittayatakorn P, et al. Plasma levels of nitric oxide in children with congenital heart disease and increased pulmonary blood flow. J Med Assoc Thai 2007; 90: 2053-2057. (Pubitemid 350057099)
72. Best PJM, Berger PB, Miller VM, et al. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann Intern Med 1998; 128: 285-288. (Pubitemid 28090759)
73. Heiss C, Lauer T, Dejam A, et al. Plasma nitroso compounds are decreased in patients with endothelial dysfunction. J Am Coll Cardiol 2006; 47: 573-579. (Pubitemid 43170846)
74. Landim MBP, Filho AC, Chagas ACP. Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis. Clinics 2009; 64: 471-478.
75. Sydow K, Münzel T. ADMA and oxidative stress. Atherosclerosis Suppl 2003; 4: 41-51. (Pubitemid 38234494)
76. Krempl TK, Maas R, Sydow K, Meinertz T, Böger RH, Kähler J. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J 2005; 26(18): 1846-1851. (Pubitemid 41253296)
77. Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009; 119(12): 1592-1600.
78. Boos CJ, Lip GYH, Blann AD. Circulating endothelial cells in cardiovascular disease. J Am Coll Cardiol 2006; 48: 1538-1547. (Pubitemid 44550075)
79. Erdbruegger U, Haubitz M, Woywodt A. Circulating endothelial cells: a novel marker of endothelial damage. Clin Chim Acta 2006; 373: 17-26. (Pubitemid 44292176)
80. Souza JM, Peluffo G, Radi R. Protein tyrosine nitration-functional alteration or just a biomarker? Free Radic Biol Med 2008; 45: 357-366.
81. Hurst JK. Whence nitrotyrosine? J Clin Invest 2002; 109: 1287-1289. (Pubitemid 34546892)
82. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 87: 315-424. (Pubitemid 46217686)
83. Jin J, Wang C, Tao Y, et al. Determination of 3-nitrotyrosine in human urine samples by surface plasmon resonance immunoassay. Sensors Actuators B 2011; 153: 164-169.
84. Molavi B, Mehta JL. Oxidative stress in cardiovascular disease: molecular basis of its deleterious effects, its detection and therapeutic consideration. Curr Opin Cardiol 2004; 19: 488-493. (Pubitemid 39222966)
85. Lekakis J, Abraham P, Balbarini A, Blann A, Boulanger CM, Cockcroft J, et al. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Cardiovasc Prev Rehabil 2011 Mar 11. [Epub ahead of print].
86. Huang NF, Kurpinski K, Fang Q, Lee RJ, Li S. Proteomic identification of biomarkers of vascular injury. Am J Transl Res 2011; 3(2): 139-148.
87. Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson J, et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 1996; 97(8): 1989-1994. (Pubitemid 26129888)
88. Javanmard SH, Nematbakhsh M, Sanei MH. Early prevention by L-arginine attenuates coronary atherosclerosis in a model of hypercholesterolemic animals; no positive results for treatment. Nutr Metab (Lond) 2009; 6: 13.
89. Yang Z, Ming X-Z. Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin Med Res 2006; 4: 53-65.
90. Ruberg FL, Loscalzo J. Inflammation and atherothrombosis. In: Loscalzo J (ed). Molecular Mechanisms of Atherosclerosis. London: Taylor and Francis 2005: 45-60.
91. Libby P. Changing concepts of atherogenesis. J Intern Med 2000; 247: 349-358. (Pubitemid 30180037)
92. Widlansky ME, Gokce N, Keaney JF, et al. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42: 1149-1160. (Pubitemid 37188333)
93. John S, Schlaich M, Langefelm M, et al. Increased bioavailability of nitric oxide after lipid lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double blind study. Circulation 1998; 98: 211-216. (Pubitemid 28337611)